{"url_path":"/sec/asbp/10-q/2026/item-1","section_key":"item-1","section_title":"Item 1 LEGAL PROCEEDINGS**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1847345/0001493152-26-023802-index.html","accession_number":"0001493152-26-023802","cik":"0001847345","ticker":"ASBP","issuer_name":"Aspire Biopharma Holdings, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1847345/0001493152-26-023802-index.html","primary_entity_key":"0001847345","primary_entity_name":"Aspire Biopharma Holdings, Inc."},"word_count":81,"has_tables":true,"body_markdown":"**ITEM\n1. LEGAL PROCEEDINGS**\n\n \n\nAs discussed in Note 12 to the unaudited condensed consolidated financial\nstatements, in April 2026 Srirama Associates, LLC filed a lawsuit in the Superior Court of the State of Delaware alleging breach of contract\nrelated to an amended promissory note fee. The complaint seeks approximately $1,000,000 in damages, plus interest and costs. The Company\ndisputes the claim and filed a motion to dismiss on May 11, 2026. No liability has been recorded as of March 31, 2026."}